James Healy, Director at Amarin, holds 2.00M shares in Rapport Therapeutics, Inc. (Ticker: RAPP), holds 1.60M shares in Natera (Ticker: NTRA), holds 2.23M shares in Y-Mabs Therapeutics (Ticker: YMAB). Most recently, James Healy Bought ― shares of Rapport Therapeutics, Inc. on Jul 03, 2024 for an estimated value of 1.08M.
James Healy latest transaction was an Informative Buy of $1.08M.
What was James Healy's most profitable transaction?
James Healy’s most profitable transaction was an Informative Buy of KRTX stock on July 2, 2019. The return on the trade was 405.70%.
What is James Healy's role in Amarin?
James Healy's role in Amarin is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.